Last update Oct. 9, 2016

Флунаризина Гидрохлорид

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

Calcium-channel-blocking drug which is a piperazine derivative antihistamine with sedative effects.
Used in prophylaxis of migraines and dizziness.

At latest update no published data on excretion into breast milk were found.
It may increase prolactin level (from Cortelli Formisano 1985 to 1991).
Despite its high protein-binding capacity, because of a very long half-life span (18 days), there is a higher risk of excretion into breastmilk.

A known and safer alternative should be preferred until more published data on this drug related to breastfeeding is available, - e.g. Propranolol, Metoprolol, Sertraline, Escitalopram, Amitrptilina or Valproate for Migraine prophylaxis (Pringsheim 2012, Davanzo 2014) and Nimodipine, Betahistine or Ginkgo biloba for vertigo prophylaxis, especially in the neonatal period and in case of prematurity.

Alternatives

  • Amitriptyline (Safe substance and/or breastfeeding is the best option.)
  • Betahistine (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Ginkgo. Ginkgo biloba (Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.)
  • Magnesium Carbonate (Safe substance and/or breastfeeding is the best option.)
  • Metoprolol (Safe substance and/or breastfeeding is the best option.)
  • Nimodipine (Safe substance and/or breastfeeding is the best option.)
  • Nortriptyline Hydrochloride (Safe substance and/or breastfeeding is the best option.)
  • Propranolol (Safe substance and/or breastfeeding is the best option.)
  • Valproate, Valproic Acid (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Флунаризина Гидрохлорид is Flunarizine Hydrochloride in Cyrillic.

Is written in other languages:

Group

Флунаризина Гидрохлорид belongs to this group or family:

Tradenames

Main tradenames from several countries containing Флунаризина Гидрохлорид in its composition:

List of 14 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. > 80 %
Molecular weight 405 daltons
Protein Binding 99 %
VD 78 l/Kg
Tmax 2 - 4 hours
T½ 432 hours

References

  1. Davanzo R, Bua J, Paloni G, Facchina G. Breastfeeding and migraine drugs. Eur J Clin Pharmacol. 2014 Abstract
  2. HPRA. Flunarizine. Drug Summary. 2014 Full text (in our servers)
  3. AEMPS. Flunarizina. Ficha técnica. 2013 Full text (in our servers)
  4. Pringsheim T, Davenport W, Mackie G, Worthington I, Aubé M, Christie SN, Gladstone J, Becker WJ; Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012 Abstract Full text (in our servers)
  5. Teive HA, Troiano AR, Germiniani FM, Werneck LC. Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis. Parkinsonism Relat Disord. 2004 Abstract
  6. Formisano R, Falaschi P, Cerbo R, Proietti A, Catarci T, D'Urso R, Roberti C, Aloise V, Chiarotti F, Agnoli A. Nimodipine in migraine: clinical efficacy and endocrinological effects. Eur J Clin Pharmacol. 1991 Abstract
  7. Cortelli P, Santucci M, Righetti F, Pirazzoli P, Albani F, Baruzzi A, Sacquegna T, Cacciari E. Neuroendocrinological evidence of an anti-dopaminergic effect of flunarizine. Acta Neurol Scand. 1988 Abstract
  8. Bonuccelli U, Piccini P, Paoletti AM, Nuti A, Colzi A, Melis GB, Muratorio A. Flunarizine increases PRL secretion in normal and in migraineous women. J Neural Transm. 1988 Abstract
  9. Maestri E, Manzoni GC, Marchesi G, Camellini L, Rossi G, Veneri G, Gnudi A. Effect of flunarizine on pituitary secretion by healthy men and in woman with migraine. Eur J Clin Pharmacol. 1987 Abstract
  10. Cortelli P, Santucci M, Righetti F, Pirazzoli P, Cacciari E, Albani F, Baldrati A, De Carolis P, Baruzzi A, Sacquegna T. Hormonal and metabolic changes induced by flunarizine therapy: preliminary results. Cephalalgia. 1985 Abstract
  11. Facchinetti F, Sances G, Bakalakis C, Morgillo MG, Lottici P, Cicoli C, Genazzani AR. Neuroendocrine effects of flunarizine treatment in postmenopausal women. Cephalalgia. 1985 Abstract
  12. Flor SC. Determination of the calcium antagonist flunarizine in biological fluids by gas-liquid chromatography. J Chromatogr. 1983 Abstract
  13. Woestenborghs R, Michielsen L, Lorreyne W, Heykants J. Sensitive gas chromatographic method for the determination of cinnarizine and flunarizine in biological samples. J Chromatogr. 1982 Abstract

Total visits

2,227

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche de México of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM